Patents Represented by Attorney Robert J. Baran

Find this attorney in the Justia Lawyer Directory

  • Botulinum toxin therapy for Hashimoto's thyroiditis
    Patent number: 6773711
    Abstract: Methods for treating the hypothyroidism of Hashimoto's thyroiditis by local administration of a neurotoxin, such as a botulinum toxin, to the thyroid gland of a patient.
    Type: Grant
    Filed: October 30, 2001
    Date of Patent: August 10, 2004
    Assignee: Allergan, Inc.
    Inventors: Martin A. Voet, Stephen Donovan
  • 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
    Patent number: 6767920
    Abstract: The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; wherein hatched lines represent the &agr; configuration, a triangle represents the &bgr; configuration, a wavy line represents the &agr; configuration or the &bgr; configuration and a dotted line represents the presence or absence of a double bond; A and B are independently selected from the group consisting of O, S and CH2; provided that at least one of A or B is S; D represents a covalent bond or CH2, O, S or NH; X is CO2R, CONR2, CH2OR, P(O)(OR)2, CONRSO2R SONR2 or Y is O, OH, OCOR2, halogen or cyano; Z is CH2 or a covalent bond; R is H or R2; R1 is H, R2, phenyl, or COR2; R2 is C1-C5 lower alkyl or alkenyl and R3 is benzothienyl, benzofuranyl, naphthyl or substituted derivatives thereof, wherein the substituents may
    Type: Grant
    Filed: January 16, 2003
    Date of Patent: July 27, 2004
    Assignee: Allergan, Inc.
    Inventors: Robert M. Burk, Mark Holoboski, Mari F. Posner
  • Methods for treating cardiovascular diseases with botulinum toxin
    Patent number: 6767544
    Abstract: The present invention provides for methods of treating cardiovascular diseases in a mammal. The methods include a step of administering an effective amount of a botulinum toxin directly to a blood vessel of a mammal thereby treating a cardiovascular disease.
    Type: Grant
    Filed: April 1, 2002
    Date of Patent: July 27, 2004
    Assignee: Allergan, Inc.
    Inventors: Gregory F. Brooks, Stephen Donovan
  • 3-(Arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
    Patent number: 6765012
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: July 20, 2004
    Assignee: Allergan, Inc.
    Inventors: Steven W. Andrews, Julie A. Wurster, Edward H. Wang, Thomas Malone
  • 5,6,7,8-tetrahydronaphthalen-2-yl 2,6-difluoroheptatrienoic acid derivatives having serum glucose reducing activity
    Patent number: 6759547
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effect of reducing serum thyroxine levels.
    Type: Grant
    Filed: January 14, 2003
    Date of Patent: July 6, 2004
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Haiqing Yuan, Yang-Dar Yuan, Roshantha A. Chandraratna
  • 3,5-di-iso-propyl-heptatrienoic acid derivatives having serum glucose reducing activity
    Patent number: 6759546
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effect of reducing serum thyroxine levels.
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: July 6, 2004
    Assignee: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Richard L. Beard, Haiqing Yuan, Roshantha A. Chandratratna
  • Kinase inhibitors for the treatment of disease
    Patent number: 6747025
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell poliferation.
    Type: Grant
    Filed: March 13, 2003
    Date of Patent: June 8, 2004
    Assignee: Allergan, Inc.
    Inventors: Steven W. Andrews, Michael E. Garst, Xialing Guo, Jonathan J. Hebert, Thomas Malone, Julie A. Wurster, Clarence Eugene Hull, III
  • Piperidinyl prostaglandin E analogs
    Patent number: 6747037
    Abstract: The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; wherein X, Y, Z, D and R3 are as defined in the specification.
    Type: Grant
    Filed: June 6, 2003
    Date of Patent: June 8, 2004
    Assignee: Allergan, Inc.
    Inventors: David W. Old, Thang D. Dinh
  • Method for treating hyperthyroidism
    Patent number: 6743424
    Abstract: A method for treating hypothyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a thyroid, thereby reducing an inhibitory effect upon thyroid hormone secretion. A method for treating hyperthyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a sympathetic ganglion which innervates the thyroid, thereby reducing a stimulatory effect upon thyroid hormone secretion. Methods for treating calcium metabolism disorders by local administration of a neurotoxin to modulate calcitonin secretion are also disclosed.
    Type: Grant
    Filed: November 2, 2000
    Date of Patent: June 1, 2004
    Assignee: Allergan, Inc.
    Inventor: Stephen Donovan
  • Method for treating thyroid disorders with a botulinum toxin
    Patent number: 6740321
    Abstract: A method for treating hypothyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a thyroid, thereby reducing an inhibitory effect upon thyroid hormone secretion. A method for treating hyperthyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a sympathetic ganglion which innervates the thyroid, thereby reducing a stimulatory effect upon thyroid hormone secretion. Methods for treating calcium metabolism disorders by local administration of a neurotoxin to modulate calcitonin secretion are also disclosed.
    Type: Grant
    Filed: November 2, 2000
    Date of Patent: May 25, 2004
    Assignee: Allergan, Inc.
    Inventor: Stephen Donovan
  • (1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity
    Patent number: 6734193
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification are capable of reducing serum glucose levels in diabetic mammals without the undesirable side effects of reducing serum thyroxine levels and transiently increasing triglyceride levels.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: May 11, 2004
    Assignee: Allergan, Inc.
    Inventors: Tien Duong, Richard L. Beard, Roshantha A. Chandraratna
  • 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
    Patent number: 6734206
    Abstract: The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; wherein X, Y, Z, D and R3 are as defined in the specification.
    Type: Grant
    Filed: June 2, 2003
    Date of Patent: May 11, 2004
    Assignee: Allergan, Inc.
    Inventors: David W. Old, Thang D. Dinh, Robert M. Burk
  • 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
    Patent number: 6734201
    Abstract: The present invention provides a compound represented by the general formula I; wherein A, Ar, X, Z, n, x, y, R and R3 are as defined in the specification.
    Type: Grant
    Filed: June 2, 2003
    Date of Patent: May 11, 2004
    Assignee: Allergan, Inc.
    Inventors: David W. Old, Thang D. Dinh, Robert M. Burk
  • Tazarotene and alpha hydroxy acid treatment for psoriasis and/or photodamage
    Patent number: 6730308
    Abstract: The present invention relates to a method of treating psoriasis and/or photo damage in humans with tazarotene in a topical composition from 0.01 to 15% by weight tazarotene, and an alpha or beta-hydroxy acid in a topical composition comprising from 1 to 25% by weight alpha or beta-hydroxy acid. Furthermore, the present invention relates to treating or preventing psoriasis and/or photo damage by topically applying to the skin of a human, tazarotene, such as a gel comprising 0.01% to 0.1%, tazarotene by weight, and an alpha hydroxy acid, such as a cream, comprising 5% to 20% alpha hydroxy acid, e.g. glycolic acid, by weight.
    Type: Grant
    Filed: March 8, 1999
    Date of Patent: May 4, 2004
    Assignee: Allergan, Inc.
    Inventor: John Sefton
  • Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
    Patent number: 6720423
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification, are specific or selective agonists of RXR retinoid receptors.
    Type: Grant
    Filed: April 30, 2002
    Date of Patent: April 13, 2004
    Assignee: Allergan, Inc.
    Inventors: Jayasree Vasudevan, Dehua Huang, Vidyasagar Vuligonda, Roshanta S. Chandraratna
  • Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
    Patent number: 6720425
    Abstract: Compounds of the formula where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.
    Type: Grant
    Filed: December 9, 2002
    Date of Patent: April 13, 2004
    Assignee: Allergan, Inc.
    Inventors: Alan T. Johnson, Min Teng, Vidyasagar Vuligonda, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Roshantha A. Chandraratna
  • Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2&agr; antagonists
    Patent number: 6716864
    Abstract: The present invention provides novel compounds represented by the general formula I. wherein m, n, X, Y, Z, R, R1 and R2 are as defined in the specification or a pharmaceutically acceptable salt thereof. The novel compounds are PGF2&agr; antagonists, useful in pharmaceutical compositions for treating PGF2&agr;-mediated disease responses such as inflammatory reactions relating to rheumatoid arthritis and psoriasis, reproductive disorders, bronchoconstrictive disorders (asthma), excessive bone breakdown (osteoporosis), peptic ulcers, heart disease, platelet aggregation and thrombosis.
    Type: Grant
    Filed: November 19, 2002
    Date of Patent: April 6, 2004
    Assignee: Allergan, Inc.
    Inventors: Robert M. Burk, Yariv Donde
  • Cyclopentane(ENE)heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
    Patent number: 6716876
    Abstract: The invention relates to 7-[5-hydroxy-2-(hydroxyhydrocarbyl or heteroatom-substituted hydroxy hydrocarbyl)-3-hydroxy-cyclopentyl(enyl)] heptanoic or heptenoic acids and derivatives of said acids, wherein one or more of said hydroxy groups are replaced by an ether group. The compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: April 6, 2004
    Assignee: Allergan, Inc.
    Inventor: Robert M. Burk
  • Method for treating hypocalcemia
    Patent number: 6716427
    Abstract: A method for treating hypothyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a thyroid, thereby reducing an inhibitory effect upon thyroid hormone secretion. A method for treating hyperthyroidism by local administration of a neurotoxin, such as a botulinum toxin, to a sympathetic ganglion which innervates the thyroid, thereby reducing a stimulatory effect upon thyroid hormone secretion. Methods for treating calcium metabolism disorders by local administration of a neurotoxin to modulate calcitonin secretion are also disclosed.
    Type: Grant
    Filed: November 2, 2000
    Date of Patent: April 6, 2004
    Assignee: Allergan, Inc.
    Inventor: Stephen Donovan
  • Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
    Patent number: 6713268
    Abstract: Methods to identify agents having ocular hypotensive activity which have reduced or absent ability to stimulate iridial hyperpigmentation are disclosed. The methods reside in part in detecting the ability of a test compound to interact with the FP receptor.
    Type: Grant
    Filed: June 26, 2001
    Date of Patent: March 30, 2004
    Assignee: Allergan, Inc.
    Inventors: David F. Woodward, Licheng Shi, Achim H-P Krauss, Clayton S. Spada, Sheila Mac Neil, Linda C. Smith-Thomas